Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Elemental sulfur or compound thereof
Patent
1996-07-24
2000-04-04
Wortman, Donna C.
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Elemental sulfur or compound thereof
514665, A01N 5902
Patent
active
060458321
DESCRIPTION:
BRIEF SUMMARY
This is a national phase filing of the Application No. PCT/EP94/02505, which was filed with the Patent Cooperation Treaty on Jul. 28, 1994, and is entitled to priority of the German Patent Application No. P 43 25 547.7, filed Jul. 29, 1993.
I. FIELD OF THE INVENTION
The present invention relates to a new use of thiol compounds for the preparation of a pharmaceutical composition for treating virus-modified diseases. In particular, this invention concerns a use of thiol compounds for the preparation of a pharmaceutical composition for treating virus-induced disease, the thiol compounds used destroying disulfide bridges present in proteins.
II. BACKGROUND OF THE INVENTION
Acute and chronic infections of plants, animals and man, caused by various viral pathogens, represent a serious medical and economic problem. In fact, presumably 60% of the diseases occurring in the industrialized countries are caused by viruses. Thus, diseases caused by hepatitis viruses, for example, are counted among the most frequent infections world-wide. Since said viral infections substantially affect the liver, the progressive destruction of this organ, followed by a subsequent development of a cirrhosis, may finally result in the formation of a hepatocellular carcinoma.
A high specificity degree for the viral pathogen and the simultaneous absence or minimization of health-damaging side-effects have to be regarded as an essential demand to be made on an antiviral therapeutic agent. In this connection, the close linkage of the viral reproductive cycle with the metabolic and replicative functions of the host cell prove to be especially problematic. For the time being, medical research focuses on the development of antiviral agents which impair or prevent the replication of the viral genome, great importance being attached particularly to chemically synthesized nucleoside analogues.
However, one of the main problems of antiviral chemotherapy has to be seen in the fact that no effective substances for therapeutic treatment are available for plurality of significant infective agents such as the hepatitis B virus, for example.
Correspondingly, the present invention is based on the technical problem of providing further therapeutically active and simultaneously pharmaceutically compatible substances for controlling viral diseases.
The solution to this technical is achieved by providing the embodiments characterized in more detail in the claims. In particular, the technical problem is solved in that the present invention discloses the therapeutically active use of thiol compounds for the preparation of a pharmaceutical composition for controlling virus-induced diseases, disulfide bridges present in viral proteins being destroyed by the thiol compounds.
III. SUMMARY OF THE INVENTION
The present invention relates to the new use of thiol compounds for the preparation of a pharmaceutical composition for treating virus-induced disease. In particular, the invention concerns the use of thiol compounds for the preparation of a pharmaceutical composition for treating virus-induced disease, the thiol compounds used destroying disulfide bridges present in viral proteins.
IV. BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows the content, i.e. the amount detected via immunological interaction between viral surface antigen and commercially obtainable antibody, of the viral antigen HBsAG in the cell culture supernatant of HepG2-4A5 cells after treatment with various NAC concentrations as a function of time.
FIG. 2 shows the content of the viral antigen HBeAg in the cell culture supernatant of HepG2-4A5 cells after treatment with various NAC concentrations as a function of time.
FIG. 3A shows the content of intact HBV viral particles in the cell culture supernatant of HepG2-4A5, the cell line HepG2-4A5 having been incubated additionally with 30 nM NAC concentrations. As a control, the cell supernatant of the cell line HepG2 is shown which does not produce HBV particles (ATCC HB 8065). See, Nature, 1979, 282:615-616.
FIG. 3B shows the content of int
REFERENCES:
patent: 4378351 (1983-03-01), Petrovich
patent: 4474759 (1984-10-01), Petrovich
patent: 4708965 (1987-11-01), Morgan
Murphy, F.A., "Virus Taxonomy", pp. 15-57, in Fields Virology, third ed., ed. Fields et al., Lippincott-Raven Publishers, Philadelphia, 1996.
Fenner, F., "Poxviruses", pp. 2673-2702, in Fields Virology, third ed., ed. Fields et al., Lippincott Publishers, Phidelphia 1996.
Flora, et al., "Antioxidant activity and other mechanisms of thiols involved in chemoprevention of mutation and cancer", The American Journal of Medicine, pp. 3C 122-130S Sep. 30, 1991.
Wirth, M.P., "Noveaux medicaments pour le traitment des affections respiratoires", Brevet Special De Medicament, No. 4.619 M, pp. 1-3, Nov. 15, 187.
Roederer et al., "N-acetylcysteine inhibits latent HIV expression in chronically infected cells", AIDs Research and Human Retroviruses, 7/6:563-567,. 1991.
Roederer et al., "N-acetylcysteine: a new approach to anti-HIV therapy", AIDS Research and Human Retroviruses, 8/2:209-217, Feb. 1992.
Beloqui et al., "N-acetyl cysteine enhances the response to interferon-alpha in chronic hetpatitis C: a pilot study", Journal of Interferon Research 13:279-282, 1993.
Droge et al., "Modulation of lymphocyte functions and immune responses by cysteine and cysteine derivatives", The American Journal of Medicine 91, suppl. 3C:140S-144S Sep. 1991.
Database Medline on dialog, No. 06557599, Karg et al., "Glutathione in human melanoma cells. Effects of cysteine, cysteine esters and glutathione isopropyl ester", J. Dermatol. Sci., 1(1):39-45, Jan. 1990.
Translation of French Patent No. 4,619, Novel Medications for the Treatment of Respiratory Disorders, pp. 1-8, Jan. 1967.
Aden et al., 1979, "Cntrolled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line," Nature 282:615-616.
Roederer et al., 1990, "Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine," Proc. natl. Acad. Sci. U.S.A. 84:4884-4888.
Sells et al., 1987, "Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA," Proc. Natl. Acad. Sci. U.S.A. 84:1005-1009.
Toyoshima et al., 1979, "Disinfectant for hepatitus B virus," Chemical Abstracts 90: Abstract. No. 66875d.
Brumback Brenda G.
Ludwig Weiss
Wortman Donna C.
LandOfFree
Use of DACEE and Derivatives for treating viral diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of DACEE and Derivatives for treating viral diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of DACEE and Derivatives for treating viral diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-362564